发明名称 |
Composition For Prevention of Vasoactivity in the Treatment of Blood Loss and Anemia |
摘要 |
The present invention relates to the prevention of cardiovascular and central nervous system side effects in mammals who receive transfusions of hemoglobin based oxygen carriers (HBOC) or stored blood products containing a concentration of hemoglobin sufficient to induce vasoconstriction, by adding a vasoactivity reducing effective amount of one or more phosphodiesterase inhibitors in combination with a calcium channel blocker and/or an alpha agonist, to the circulation, or alternatively to the HBOC or stored blood, thereby preventing the manifestation of vasoactivity attributable to the presence of free tetrameric hemoglobin (Hb). |
申请公布号 |
US2015290213(A1) |
申请公布日期 |
2015.10.15 |
申请号 |
US201414252318 |
申请日期 |
2014.04.14 |
申请人 |
BLUMENSTEIN Jan |
发明人 |
BLUMENSTEIN Jan |
分类号 |
A61K31/554;A61K45/06;A61K31/517;A61K31/519;A61K31/53 |
主分类号 |
A61K31/554 |
代理机构 |
|
代理人 |
|
主权项 |
1. A process for reducing or preventing vasoactivity induced by the introduction of a composition containing a hemoglobin based oxygen carrier (HBOC), free hemoglobin (Hb), stored blood products having vasoactivity inducing concentrations of free tetrameric hemoglobin, and combinations thereof comprising:
combining at least one phosphodiesterase inhibitor (PDE) with at least one calcium channel blocker, and at least one alpha antagonist, with an HBOC or Hb containing material, in an amount effective to reduce or prevent said vasoactivity. |
地址 |
Toronto CA |